Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24526785 | 0.73 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL21693510 | 0.73 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL21720092 | 0.73 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL24191714 | 0.73 | HPGD (0.35) | HSD11B1 | |
| SCHEMBL21720075 | 0.73 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL19696515 | 0.70 | ALDH1A1 (0.32) | — | |
| SCHEMBL23477043 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL21720093 | 0.69 | — | — | |
| SCHEMBL20807382 | 0.66 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL9596247 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022103983-A9 | FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022103983-A2 | FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9566278-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-03-03 | — | — | US | disclosed |
| WO-2016029454-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | TSHR 4013/4885MEN1 1944/4885KMT2A 1250/4885 |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIN2C, GRIN2B | TSHR 859/4885MEN1 3852/4885KMT2A 725/4885 |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | TSHR 2105/4885MEN1 274/4885KMT2A 3917/4885 |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | TSHR 2330/4885MEN1 4419/4885KMT2A 4147/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 985/4885MEN1 749/4885KMT2A 2207/4885 |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | LIPA, IDE, CEL | TSHR 3700/4885MEN1 2843/4885KMT2A 1061/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | TSHR 520/4885MEN1 3376/4885KMT2A 1237/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | TSHR 2105/4885MEN1 274/4885KMT2A 3917/4885 |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | TSHR 3710/4885MEN1 3946/4885KMT2A 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.